MissionIRNewsBreaks – Jupiter Neurosciences Inc. (NASDAQ: JUNS) Closes $2 Million Registered Direct OfferingJupiter Neurosciences (
NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering with gross proceeds of approximately $2.0 million.
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct OfferingNEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (
NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (
NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public.
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Jupiter Neurosciences, Inc. (
NASDAQ: JUNS) resulting from allegations that Jupiter Neurosciences may have issued materially misleading business information to the investing public.
Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingNEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing.
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12thCompany Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com
Jupiter Neurosciences Selected as B2i Digital Featured CompanySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Jupiter Neurosciences Selected as B2i Digital Featured CompanyClinical-Stage Pharmaceutical Company Advancing Phase IIa Parkinson’s Trial
From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The HorizonSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The HorizonDETROIT, MICHIGAN - December 16, 2025 ( NEWMEDIAWIRE ) - Jupiter Neurosciences Inc. (
NASDAQ: JUNS), the clinical-stage pharmaceutical company developing JOTROL, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects, is ending the year on a high note hitting several milestones in its first year as a public company.
Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Are CustomersDETROIT, MICHIGAN - November 6, 2025 ( NEWMEDIAWIRE ) - When it comes to brain health, Jupiter Neurosciences Inc. (
NASDAQ: JUNS) knows a thing or two about it. After all, the clinical-stage pharmaceutical company developing JOTROL™, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects, has developed Nugevia™, a direct-to-consumer longevity product line, aimed at improving mitochondrial support, mental clarity and "beauty from within."
Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With BenzingaDETROIT, MICHIGAN - August 21, 2025 ( NEWMEDIAWIRE ) - Christer Rosen, Chairman and CEO, and Alison Silva, President and CBO at Jupiter Neurosciences Inc . (
NASDAQ: JUNS), sat down with Benzinga to discuss how the company is addressing longevity and brain health with JOTROL™ and its new direct-to-consumer product line, Nugevia.
